Patents Issued in June 13, 2017
  • Patent number: 9676840
    Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 13, 2017
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Terrence Lee Fisher
  • Patent number: 9676841
    Abstract: The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: June 13, 2017
    Assignees: Novartis AG, Massachusetts Institute of Technology
    Inventors: Naresh Chennamsetty, Bernhard Helk, Veysel Kayser, Bernhardt Trout, Vladimir Voynov
  • Patent number: 9676842
    Abstract: A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: June 13, 2017
    Assignee: NOVELMED THERAPEUTICS, INC.
    Inventor: Rekha Bansal
  • Patent number: 9676843
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 13, 2017
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gnoth, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
  • Patent number: 9676844
    Abstract: Pharmaceutical compositions and methods for the treatment of DENND1 A. V2 related disorders, such as PCOS, are provided. In particular, humanized and mouse monoclonal antibodies specific for DENND1 A. V2 and methods for using the same are provided.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: June 13, 2017
    Assignees: Virginia Commonwealth University, The Penn State Research Foundation
    Inventors: Janette M. McAllister, Jerome F. Strauss, Neil D. Christensen
  • Patent number: 9676845
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: June 13, 2017
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Sabine Imhof-Jung, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer
  • Patent number: 9676846
    Abstract: Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: June 13, 2017
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Qi Zhao
  • Patent number: 9676847
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: June 13, 2017
    Assignee: Orega Biotech
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Patent number: 9676848
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 13, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9676849
    Abstract: The invention is based, at least in part, on the finding that a dimeric version of a BBB-transmigrating antibody (e.g., the TMEM30A (CDC-50A) binding antibody, FC5) was found to greatly enhance transport across the BBB as compared to monovalent FC5 VHH. The invention provides, inter alia, molecules that increase transport of pharmacologically active agents across the blood brain barrier, methods for increasing transport across the blood brain barrier, and methods of treatment of disorders or diseases having a neurological component.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: June 13, 2017
    Assignee: Biogen MA Inc.
    Inventors: Graham K. Farrington, William Sisk
  • Patent number: 9676850
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 13, 2017
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Laura Saunders, Scott J. Dylla, Orit Foord, Robert A. Stull, Michael Torgov, Hui Shao, David Liu
  • Patent number: 9676851
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 13, 2017
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Patent number: 9676852
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: June 13, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 9676853
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: May 31, 2014
    Date of Patent: June 13, 2017
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Patent number: 9676854
    Abstract: The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: June 13, 2017
    Assignee: MedImmune, LLC
    Inventors: Linda Liu, Shannon Marshall, Solomon Langermann
  • Patent number: 9676855
    Abstract: The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: June 13, 2017
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Adelheid Cerwenka, Gerhard Moldenhauer
  • Patent number: 9676856
    Abstract: Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of B7-H7 to B7-HrCR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. In another aspect, the therapeutic agents modulate the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. The therapeutic agents can be used in the prevention, treatment and/or management of diseases in which it might be useful to modulate one or more immune functions (e.g., cancer, infectious disease, autoimmune disease, and transplantation rejection). In another aspect, presented herein are methods for identifying receptor-ligand interactions.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: June 13, 2017
    Assignee: The Johns Hopkins University
    Inventor: Lieping Chen
  • Patent number: 9676857
    Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 13, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Tianlei Ying
  • Patent number: 9676858
    Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These may be used as therapeutic agents.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: June 13, 2017
    Assignees: Duke University, The United States of America as represented by the secretary, Department of Health and Human Services (NIH)
    Inventors: Darell Bigner, Chien-Tsun Kuan, John Sampson, Bryan Choi, Ira H. Pastan, Patrick C. Gedeon
  • Patent number: 9676859
    Abstract: The invention is generally directed to promoting dendritic cells (DCs), and optionally M1-type (macrophage M1 polarization), immune response by administering a compound that modulates macrophage polarization. The invention is directed to the use of an antibody able to bind to CSF-1R for modulating macrophage polarization. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-1R in a patient by assessing the in vivo or in vitro polarization of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-1R on a subject being treated.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: June 13, 2017
    Assignee: Transgene SA
    Inventors: Hélène Haegel, Rémy Hallet
  • Patent number: 9676860
    Abstract: The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: June 13, 2017
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Taymar E. Hartman, Paul W. Sauer, John E. Burky, Mark C. Wesson, Ping Y. Huang, Thomas J. Robinson, Braeden D. Partridge, J. Yun Tso
  • Patent number: 9676861
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 13, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9676862
    Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10?10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: June 13, 2017
    Assignee: ALLIGATOR BIOSCIENCE, AB
    Inventors: Peter Bo Joakim Ellmark, Eva Maria Dahlen
  • Patent number: 9676863
    Abstract: This invention relates generally to bifunctional molecules including (a) a TGF?RII or fragment thereof capable of binding TGF? and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: June 13, 2017
    Assignee: Merck Patent GmbH
    Inventor: Kin-Ming Lo
  • Patent number: 9676864
    Abstract: The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: June 13, 2017
    Assignee: SANOFI
    Inventors: Herve Bouchard, Alain Commercon, Claudia Fromond, Vincent Mikol, Fabienne Parker, Ingrid Sassoon, Daniel Tavares
  • Patent number: 9676865
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: June 13, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. Lewicki, Austin L. Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Patent number: 9676866
    Abstract: The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a CA 125/O772P-related disorder. In particular, the present invention provides methods of preventing, managing, treating, or ameliorating one or more symptoms associated with a cell proliferative disorder, such as cancer, e.g., ovarian cancer. The present invention still further provides methods for diagnosing a CA 125/O772P-related disorder or predisposition to developing such a disorder, as well as methods for identifying antibodies, and antigen-binding fragments of antibodies, that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: June 13, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Earl F. Albone, Daniel A. Soltis
  • Patent number: 9676867
    Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: June 13, 2017
    Assignee: Dana-Farber Cancer Institute Inc.
    Inventors: Wayne A. Marasco, Agnes Lo, Chen Xu
  • Patent number: 9676868
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: June 13, 2017
    Assignee: GENENTECH, INC.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • Patent number: 9676869
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: June 13, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 9676870
    Abstract: The technology described herein is directed to methods of treating cardiovascular and metabolic disorders.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: June 13, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Guo-Ping Shi
  • Patent number: 9676871
    Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: June 13, 2017
    Assignees: PFIZER INC., RINAT NEUROSCIENCE CORP.
    Inventors: Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Shelton, Shu-Hui Liu, Jaume Pons, Russell Dushin
  • Patent number: 9676872
    Abstract: The present invention pertains to an affinity tag system for the immobilization and/or purification of molecules such as biological or organic molecules. The invention provides EF-hand subdomains of calcium binding proteins, such as calbindin D9k, as affinity tags and affinity ligands for immobilizing, detecting and/or for purifying molecules, particularly proteins. Also provided are methods utilizing the affinity tag system of the invention, affinity matrices comprising EF-hand subdomain affinity ligands and fusion proteins comprising EF-hand subdomain affinity tags.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: June 13, 2017
    Assignee: Northwestern University
    Inventors: David O'Connell, Sara Linse, Eva Thulin, Alejandro Merino
  • Patent number: 9676873
    Abstract: Bleached dextrin compositions, methods of forming the same, and products formed therefrom. The composition comprises a dextrin-based composition or slurry, a caustic agent, and an oxidant. The caustic agent may include sodium hydroxide. The oxidant may include hydrogen peroxide.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: June 13, 2017
    Assignee: Archer Daniels Midland Company
    Inventor: Normand Germain
  • Patent number: 9676874
    Abstract: Disclosed herein are metallated aminosilane compounds for use as functional initiators in anionic polymerizations and processes for producing an aminosilane-functionalized polymer using the metallated aminosilane compounds to initiate anionic polymerization of at least one type of anionically polymerizable monomer. Preferred use of the metallated aminosilane compounds results in rubber compositions for use in tires comprising an aminosilane functionalized polymer. A telechelic polymer may result from use of the metallated aminosilane compound and a functional terminator.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: June 13, 2017
    Assignee: Bridgestone Corporation
    Inventors: David F. Lawson, Terrence E. Hogan, Christine Rademacher, David M. Roggeman, Fuminori Ota
  • Patent number: 9676875
    Abstract: The present teachings show that it is possible to polymerize 1,1-disubstituted alkene compounds in a solution (for example using one or more solvents). Polymerization of 1,1-disubstituted alkene compounds in an solution provides opportunities to better control the polymerization compared with bulk polymerization. The solution polymerization techniques can be employed for preparing homopolymers, copolymers (e.g., random copolymers), and block copolymers.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: June 13, 2017
    Assignee: SIRRUS, INC.
    Inventors: Aniruddha Palsule, Alexander R. Holzer, Peter Rulon Stevenson, Kshitij Kishen Parab, Jeffrey M. Sullivan
  • Patent number: 9676876
    Abstract: The present invention provides a process for preparation of a solid titanium catalyst component for use as pro-catalyst for a Ziegler-Natta catalyst system. The solid titanium catalyst component comprises a combination of 15 to 20 wt % of a magnesium moiety, 1.0 to 6.0 wt % of a titanium moiety and 5.0 to 20 wt % of an internal donor, said solid titanium catalyst component has an average particle size in the range of 1 to 100 ?m, characterized by a three point particle size distribution of D10 in the range of 1 to 10 ?m; D50 in the range of to 25 ?m and D90 in the range of 15 to 50 ?m. The present invention also provides a 15 Ziegler-Natta catalyst system comprising the solid titanium catalyst component and the method of polymerizing and/or copolymerizing olefins by using the Ziegler-Natta catalyst system.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: June 13, 2017
    Assignee: INDIAN OIL CORPORATION LIMITED
    Inventors: Gurmeet Singh, Naresh Kumar, Sukhdeep Kaur, Gurpreet Singh Kapur, Shashi Kant, Biswajit Basu, Ravinder Kumar Malhotra, Svein Nenseth, Jarmo Lindroos
  • Patent number: 9676877
    Abstract: Disentangled high or ultrahigh molecular weight polyethylene ((U)HMWPE) being produced with a Ziegler-Natta catalyst, characterized by (i) a factor for the normalized elastic modulus G?0/G?P of less than 0.95 determined in a dynamic time sweep measurement at 180° C. with constant strain of 0.5% at fixed frequency of 10 rad/s for at least 3600 s, whereby G?0 is the elastic shear modulus measured at t0 directly after melting the sample and G?p is the maximum plateau modulus.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 13, 2017
    Assignee: BOREALIS AG
    Inventors: Thomas Hjertberg, Alexandra Romina Albunia, Yi Liu, Qizheng Dou
  • Patent number: 9676878
    Abstract: The process begins by obtaining a first batch of monomers selected from a group of acrylates with a molecular weight equal to or less than butyl acrylate and/or methacrylate with a molecular weight equal to or less than butyl methacrylate. A second batch of monomers is then selected from a group of acrylates with a molecular weight greater than butyl acrylate and/or methacrylate with a molecular weight greater than butyl methacrylate. A mixture is then prepared by mixing the first batch of monomers and the second batch of monomers, wherein the second batch of monomers are greater than 50% by weight of the mixture. Finally, the mixture is polymerized to produce an ultra high molecular weight polymer.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: June 13, 2017
    Assignee: LiquidPower Specialty Products Inc.
    Inventors: Zhiyi Bao, Stuart N. Milligan, Michael Olechnowicz
  • Patent number: 9676879
    Abstract: An object of the invention is to provide a solid polyaluminoxane composition suitably used as a cocatalyst and a catalyst carrier in combination with an olefin oligomerization or polymerization catalyst, without the use of solid inorganic carriers such as silica. The solid polyaluminoxane composition of the invention includes a polyalkylaluminoxane and a trialkylaluminum, and has a solubility in n-hexane at 25° C. of less than 0.50 mol % as measured by a specific method (i), a solubility in toluene at 25° C. of less than 1.0 mol % as measured by a specific method (ii), and a 13 mol % or more molar fraction of alkyl groups derived from the trialkylaluminum moieties relative to the total number of moles of alkyl groups derived from the polyalkylaluminoxane moieties and the alkyl groups derived from the trialkylaluminum moieties as measured with respect to tetrahydrofuran-d8 soluble components by a specific method (iii).
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: June 13, 2017
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Kou Tsurugi, Shiori Hanada, Atsushi Shibahara, Kazumori Kawamura, Fumiaki Nishino, Yasuyuki Harada, Wataru Yamada, Akiko Matsumoto, Isao Hara, Tatsuya Nakamura, Toshihiro Muroto
  • Patent number: 9676880
    Abstract: Embodiments for a crosslinked alkoxysilyl polynorbornene homopolymer and methods of making crosslinked alkoxysilyl polynorbornene homopolymer are provided, where the method comprises polymerizing through addition polymerization or ring opening metathesis polymerization a norbornene monomer comprising an alkoxysilyl moiety in the presence of a catalyst to produce an alkoxysilyl modified polynorbornene homopolymer, and producing a crosslinked alkoxysilyl polynorbornene homopolymer through sol-gel initiated crosslinking of the alkoxysilyl modified polynorbornene homopolymer at ambient conditions, or acid-catalyzed conditions.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: June 13, 2017
    Assignee: Saudi Arabian Oil Company
    Inventors: Benjamin J. Sundell, John A. Lawrence, III
  • Patent number: 9676881
    Abstract: The present invention provides a polybutadiene having improved workability and abrasion resistance. A polybutadiene according to the present invention has: (A) a Mooney viscosity (ML1+4,100° C.) being 43 or more; (B) a ratio (Tcp/ML1+4,100° C.) of 5 wt % toluene solution viscosity (Tcp) to Mooney viscosity (ML1+4,100° C.) being 0.9 to 2.3; (C) a stress relaxation time (T80) being 10.0 to 40.0 seconds, which is a time until a torque is attenuated by 80% when the torque at the end of ML1+4,100° C.measurement is 100%; and (D) a molecular weight distribution (Mw/Mn) being 2.50 to 4.00.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: June 13, 2017
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Mitsuharu Ambe, Yuuto Kanou, Takeshi Shoda
  • Patent number: 9676882
    Abstract: This invention relates to processes using staged hydrogen addition in propylene polymerization. Using this process, broad/bi-modal MWD iPP with excellent stiffness properties and melt flow rates were produced.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 13, 2017
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Matthew W. Holtcamp, Jian Yang, Celestino M. Perez, Jr., Gregory S. Day, Rohan A. Hule
  • Patent number: 9676883
    Abstract: The present disclosure relates to propylene-ethylene copolymers comprising an ethylene content of 0.1-10% by weight, a molecular weight distribution (MWD), expressed in terms of Mw/Mn, of greater than 3.0 and a xylene soluble (XS) fraction content defined by values that fall below the line given by the equation XS=1.0296·e0.435C2. The propylene-ethylene copolymers advantageously exhibit high transparency and low melting temperatures.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: June 13, 2017
    Assignee: Basell Poliolefine Italia S.r.l.
    Inventors: Fabrizio Piemontesi, Caroline Cathelin, Simona Guidotti, Dario Liguori, Giampiero Morini, Davide Tartari, Gianni Vitale
  • Patent number: 9676884
    Abstract: Copolymers of alpha-olefins are generally disclosed, including methods of making such copolymers. In some embodiments, copolymers of alpha-olefins and certain unsaturated ester compounds are also disclosed, including methods of making such copolymers. Lubricant compositions including copolymers of alpha-olefins are also disclosed, as well as methods of using such compositions in certain lubricant applications.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: June 13, 2017
    Assignee: Elevance Renewable Sciences, Inc.
    Inventors: Syed Q. Rizvi, Debra Tindall, Georgeta Hategan, Kristine Counter
  • Patent number: 9676885
    Abstract: Continuity compositions are provided as are methods of their preparation. The compositions comprise at least one metal carboxylate salt which is modified with at least one molten fatty amine. These compositions find advantageous use in olefin polymerization processes.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: June 13, 2017
    Assignee: Univation Technologies, LLC
    Inventors: Richard B. Pannell, David M. Glowczwski, Chi-I Kuo, Timothy R. Lynn, F. David Hussein, Phuong A. Cao, Wesley R. Mariott, Michael D. Awe
  • Patent number: 9676886
    Abstract: A novel monomer design for the synthesis of PPE-type polymers containing conjugated segments of well-defined length connected by flexible linkers under Sonogashira reaction conditions is presented. The resulting polymers retain the photophysical properties of a fully conjugated PPE. The extent of incorporation of the flexible units along the backbone is governed by the comonomer feed ratio and can be varied in a statistically predictable fashion.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: June 13, 2017
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Joong Ho Moon, Tereza Vokata
  • Patent number: 9676887
    Abstract: Structural adhesives are prepared from an elastomeric toughener that contains urethane and/or urea groups, and have some terminal isocyanate groups that are capped with a phenol and other terminal isocyanate groups that are capped with a hydroxy-functional acrylate or a hydroxy-functional methacrylate. In certain embodiments, the presence of both types of capping on the toughener leads to higher impact peel strengths and a greater level of cohesive failure, than when the toughener is capped with a phenol an hydroxy-functional acrylate or hydroxy-functional methacrylate alone.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: June 13, 2017
    Assignee: Dow Global Technologies LLC
    Inventors: Andreas Lutz, Daniel Schneider
  • Patent number: 9676888
    Abstract: To provide a novel compound having both a surface-activating ability and a polymerization controlling ability. A compound represented by the following general formula (1) or (2): wherein, R1 and R3 are an organic group having the hydrophile-lipophile balance (HLB) determined by Griffin's method of 3 or more. The definitions of R1, R2, R3, R4, Z, p and q are described in the Description.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: June 13, 2017
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Tetsuya Noda, Fuminori Nakaya, Keiichi Sakashita, Yosuke Matsunaga, Taeko Oonuma, Yoshiko Irie
  • Patent number: 9676889
    Abstract: There is described an aqueous urethane acrylate copolymer dispersion comprising a) from 10 to 95 wt-% of a polyurethane copolymer, and b) from 5 to 90 wt-% of a polyvinyl copolymer, where vinyl copolymer (b) comprises from 30 parts to 100 parts by weight of biorenewable monomer(s)—such as itaconic acid, itaconate diesters and/or diamides for example dimethyl itaconate (DMI) or dibutyl itaconate (DBI) and where optionally the composition has a residual monomer level of less than 5000 ppm.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: June 13, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Tijs Nabuurs, Gerardus Cornelis Overbeek, Ronald Tennebroek